Sinensis Life Sciences acquired by EurofinsWednesday, January 13, 2016
Sinensis is the reference laboratory for both microbiology and chemistry testing for biopharmaceutical products in the domestic market, and has a presence in Europe, Asia and the US. The company employs about 150 staff, serving the pharmaceutical and biotechnology industries throughout the Netherlands. Since inception, Sinensis has consistently grown well above Eurofins’ annual organic growth objective, and expects to generate revenues in excess of EUR 13.5m for 2015, the majority of which from biopharmaceutical products testing. The company is also active in biosafety testing and biological R&D, chemical R&D, and in cGMP manufacturing.
Sinensis’ competencies are consistent with Eurofins’ market-leading biopharmaceutical testing capabilities, and specifically with the competencies of Eurofins Lancaster, the global reference in biopharmaceutical testing. Therefore, the acquisition strengthens the Group’s geographical footprint and its position as the market leader in this stable and consistently growing pharmaceutical services segment. Furthermore, this acquisition reinforces the Group’s platform to further accelerate the deployment of the most advanced testing methodologies to support the pharmaceutical and biotechnology industries across the entire drug development cycle in Europe.
Sinensis CEO Dr. Ruud Santing ads: “On behalf of all Sinensis shareholders I’m happy that the strong market position that Sinensis and its affiliated companies have generated can be further strengthened within the globally active Eurofins Group.”
Comment from Dr. Gilles Martin, Eurofins CEO: “The acquisition of Sinensis further strengthens Eurofins’ global leadership in the rapidly-growing pharmaceutical products testing market. We look forward to strengthening Sinensis’ testing portfolio and operating footprint by providing access to the full range of services and capabilities of the Eurofins Group.”
For more information, please visit www.eurofins.com or contact:
Eurofins Investor Relations
Phone: +32-2-766 1620